Targeted cancer missile tested in stomach, pancreas & colon cancers
NCT ID NCT06864169
Summary
This study is testing an experimental drug called raludotatug deruxtecan for people with advanced cancers of the digestive system (like pancreatic, stomach, or colon cancer) that have spread or cannot be removed by surgery. The drug is designed to find cancer cells and deliver treatment directly to them. Researchers want to see if tumors shrink or disappear, how long the benefits last, and what side effects occur in about 160 participants who have already tried other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bradfordhill ( Site 0069)
Santiago, Region M. de Santiago, 8420383, Chile
-
Centre François Baclesse ( Site 0085)
Caen, Calvados, 14076, France
-
Centre Hospitalier de l'Université de Montréal ( Site 0042)
Montreal, Quebec, H2X 3E4, Canada
-
Centro de Estudios Clínicos SAGA ( Site 0064)
Santiago, Region M. de Santiago, 7501010, Chile
-
China Medical University Hospital ( Site 0267)
Taichung, 40447, Taiwan
-
Clínica UC San Carlos de Apoquindo ( Site 0066)
Santiago, Region M. de Santiago, 7620002, Chile
-
FALP ( Site 0062)
Santiago, Region M. de Santiago, 7500921, Chile
-
Faculty of Medicine Siriraj Hospital ( Site 0281)
Bangkok, Bangkok, 10700, Thailand
-
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0006)
La Rioja, F5300COE, Argentina
-
Gustave Roussy ( Site 0081)
Villejuif, Val-de-Marne, 94800, France
-
Hospital Clinic de Barcelona ( Site 0223)
Barcelona, 08036, Spain
-
Hospital General Universitario Gregorio Marañón ( Site 0225)
Madrid, 28007, Spain
-
Hospital Universitario Fundacion Jimenez Diaz ( Site 0224)
Madrid, 28040, Spain
-
Hospital Universitario Marqués de Valdecilla ( Site 0221)
Santander, Cantabria, 39008, Spain
-
Hôpitaux Universitaires de Genève (HUG) ( Site 0245)
Geneva, Canton of Geneva, 1211, Switzerland
-
Institut Català d'Oncologia (ICO) - Badalona ( Site 0222)
Badalona, Barcelona, 08916, Spain
-
Institut Regional du Cancer Montpellier ( Site 0084)
Montpellier, Herault, 34298, France
-
Instituto Medico de la Fundacion Estudios Clinicos ( Site 0007)
Rosario, Santa Fe Province, S2000CEJ, Argentina
-
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0001)
Mar del Plata, Buenos Aires, B7600FZO, Argentina
-
Mackay Memorial Hospital ( Site 0266)
Taipei, 104, Taiwan
-
Morristown Medical Center ( Site 0349)
Morristown, New Jersey, 07960, United States
-
Mt Sinai Comprehensive Cancer Center ( Site 0345)
Miami Beach, Florida, 33140, United States
-
National Cheng Kung University Hospital ( Site 0263)
Tainan, 70403, Taiwan
-
National Taiwan University Hospital ( Site 0261)
Taipei, 10002, Taiwan
-
Nefra Medical Care - CEMIC Saavedra ( Site 0008)
Buenos Aires, Buenos Aires F.D., C1431FWO, Argentina
-
Pitie Salpetriere University Hospital ( Site 0082)
Paris, Orne, 75013, France
-
Prince of Wales Hospital ( Site 0122)
Hksar, Hong Kong
-
Princess Margaret Cancer Centre ( Site 0041)
Toronto, Ontario, M5G 1X6, Canada
-
Queen Mary Hospital ( Site 0121)
Hksar, Hong Kong
-
Ramathibodi Hospital. ( Site 0282)
Bangkok, Bangkok, 10400, Thailand
-
Sibley Memorial Hospital ( Site 0372)
Washington D.C., District of Columbia, 20016, United States
-
St. Vincent Healthcare Frontier Cancer Center ( Site 0347)
Billings, Montana, 59102, United States
-
Sunnybrook Research Institute ( Site 0044)
Toronto, Ontario, M4N 3M5, Canada
-
Taichung Veterans General Hospital ( Site 0265)
Taichung, 407, Taiwan
-
Taipei Veterans General Hospital ( Site 0262)
Taipei, 112, Taiwan
-
Universitaetsspital Basel ( Site 0241)
Basel, Canton of Basel-City, 4031, Switzerland
-
Universitaetsspital Zuerich ( Site 0242)
Zurich, 8091, Switzerland
-
University Hospitals Cleveland Medical Center ( Site 0369)
Cleveland, Ohio, 44106, United States
-
University of Virginia Cancer Center ( Site 0365)
Charlottesville, Virginia, 22903, United States
-
University of Wisconsin Carbone Cancer Center ( Site 0348)
Madison, Wisconsin, 53792, United States
-
Yale New Haven Hospital ( Site 0375)
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.